FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088392367> ?p ?o ?g. }

• W2088392367 endingPage "293" @default.
• W2088392367 startingPage "286" @default.
• W2088392367 abstract "Background and Objectives The aim of this study was to evaluate the pharmacokinetics, efficacy and safety of a newly developed 10% liquid immunoglobulin preparation in patients with primary immunodeficiency diseases. This new preparation for intravenous use includes three dedicated virus clearance steps in its manufacturing process to ensure a high margin of viral safety. Materials and Methods This was a prospective, open‐label, non‐controlled, multicentre study. Twenty‐two subjects with primary immunodeficiency were treated initially with three infusions of a licensed intravenous immunoglobulin to standardize the immunoglobulin G (IgG) replacement therapy of all subjects to the same intravenous product. A total of nine infusions of the new 10% liquid preparation were subsequently administered. Results The median terminal half‐life of total IgG following administration of the new preparation was 30·1 days. Median terminal half‐lives for IgG subclasses IgG 1 , IgG 2 , IgG 3 and IgG 4 were 28·3, 31·3, 20·9 and 24·2 days, respectively. The median total serum IgG steady‐state trough level was 8·51 g/l. No severe infection episodes started after initiation of treatment with the new preparation. The median rate of mild or moderate infection episodes was 0·48 per month. A total of 194 infusions with the new 10% liquid immunoglobulin preparation were administered. The mean dose per infusion was 0·41 g/kg body weight and the maximum infusion rates recorded were 8 ml/kg/h. Adverse experiences were mostly mild and unrelated to the study drugs. Only 4% of infusions with the new product were followed by one or more related adverse experiences. Conclusion The new 10% liquid immunoglobulin preparation was well tolerated and shown to have an excellent pharmacokinetic, efficacy and safety profile. The liquid formulation provides convenience to patients and healthcare professionals." @default.
• W2088392367 created "2016-06-24" @default.
• W2088392367 creator A5008876679 @default.
• W2088392367 creator A5016726414 @default.
• W2088392367 creator A5029593862 @default.
• W2088392367 creator A5044385229 @default.
• W2088392367 creator A5054348030 @default.
• W2088392367 creator A5054512616 @default.
• W2088392367 creator A5060424533 @default.
• W2088392367 creator A5060535400 @default.
• W2088392367 creator A5070985333 @default.
• W2088392367 creator A5073316878 @default.
• W2088392367 creator A5079295958 @default.
• W2088392367 creator A5086907659 @default.
• W2088392367 date "2006-03-15" @default.
• W2088392367 modified "2023-10-17" @default.
• W2088392367 title "Prospective open‐label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo‐ or agammaglobulinemia" @default.
• W2088392367 cites W1525322611 @default.
• W2088392367 cites W1833833181 @default.
• W2088392367 cites W1975546450 @default.
• W2088392367 cites W1991326653 @default.
• W2088392367 cites W2001905490 @default.
• W2088392367 cites W2004581243 @default.
• W2088392367 cites W2005602584 @default.
• W2088392367 cites W2011917012 @default.
• W2088392367 cites W2015021660 @default.
• W2088392367 cites W2017628483 @default.
• W2088392367 cites W2019882043 @default.
• W2088392367 cites W2059698605 @default.
• W2088392367 cites W2068634332 @default.
• W2088392367 cites W2070498696 @default.
• W2088392367 cites W2087190472 @default.
• W2088392367 cites W2091907308 @default.
• W2088392367 cites W2100711023 @default.
• W2088392367 cites W2130723549 @default.
• W2088392367 cites W2324437943 @default.
• W2088392367 cites W2331501377 @default.
• W2088392367 cites W2992089985 @default.
• W2088392367 cites W4205407880 @default.
• W2088392367 cites W4254719455 @default.
• W2088392367 cites W62151259 @default.
• W2088392367 doi "https://doi.org/10.1111/j.1423-0410.2006.00764.x" @default.
• W2088392367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16635071" @default.
• W2088392367 hasPublicationYear "2006" @default.
• W2088392367 type Work @default.
• W2088392367 sameAs 2088392367 @default.
• W2088392367 citedByCount "49" @default.
• W2088392367 countsByYear W20883923672012 @default.
• W2088392367 countsByYear W20883923672013 @default.
• W2088392367 countsByYear W20883923672014 @default.
• W2088392367 countsByYear W20883923672015 @default.
• W2088392367 countsByYear W20883923672016 @default.
• W2088392367 countsByYear W20883923672017 @default.
• W2088392367 countsByYear W20883923672018 @default.
• W2088392367 countsByYear W20883923672019 @default.
• W2088392367 countsByYear W20883923672020 @default.
• W2088392367 countsByYear W20883923672021 @default.
• W2088392367 countsByYear W20883923672022 @default.
• W2088392367 countsByYear W20883923672023 @default.
• W2088392367 crossrefType "journal-article" @default.
• W2088392367 hasAuthorship W2088392367A5008876679 @default.
• W2088392367 hasAuthorship W2088392367A5016726414 @default.
• W2088392367 hasAuthorship W2088392367A5029593862 @default.
• W2088392367 hasAuthorship W2088392367A5044385229 @default.
• W2088392367 hasAuthorship W2088392367A5054348030 @default.
• W2088392367 hasAuthorship W2088392367A5054512616 @default.
• W2088392367 hasAuthorship W2088392367A5060424533 @default.
• W2088392367 hasAuthorship W2088392367A5060535400 @default.
• W2088392367 hasAuthorship W2088392367A5070985333 @default.
• W2088392367 hasAuthorship W2088392367A5073316878 @default.
• W2088392367 hasAuthorship W2088392367A5079295958 @default.
• W2088392367 hasAuthorship W2088392367A5086907659 @default.
• W2088392367 hasConcept C112705442 @default.
• W2088392367 hasConcept C126322002 @default.
• W2088392367 hasConcept C159654299 @default.
• W2088392367 hasConcept C188816634 @default.
• W2088392367 hasConcept C197934379 @default.
• W2088392367 hasConcept C203014093 @default.
• W2088392367 hasConcept C2779019163 @default.
• W2088392367 hasConcept C2780898057 @default.
• W2088392367 hasConcept C2911027401 @default.
• W2088392367 hasConcept C71924100 @default.
• W2088392367 hasConcept C8891405 @default.
• W2088392367 hasConcept C90924648 @default.
• W2088392367 hasConceptScore W2088392367C112705442 @default.
• W2088392367 hasConceptScore W2088392367C126322002 @default.
• W2088392367 hasConceptScore W2088392367C159654299 @default.
• W2088392367 hasConceptScore W2088392367C188816634 @default.
• W2088392367 hasConceptScore W2088392367C197934379 @default.
• W2088392367 hasConceptScore W2088392367C203014093 @default.
• W2088392367 hasConceptScore W2088392367C2779019163 @default.
• W2088392367 hasConceptScore W2088392367C2780898057 @default.
• W2088392367 hasConceptScore W2088392367C2911027401 @default.
• W2088392367 hasConceptScore W2088392367C71924100 @default.
• W2088392367 hasConceptScore W2088392367C8891405 @default.
• W2088392367 hasConceptScore W2088392367C90924648 @default.
• W2088392367 hasIssue "4" @default.
• W2088392367 hasLocation W20883923671 @default.

• next